Worth reading
—
Scored from 0 of 3 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.What was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-09-28
| Item | Details |
|---|
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Explains that the financing will be carried out to advance the clinical development of docirbrutinib (AS-1763) and monzosertib (AS-0141), enhance pipeline value, and maintain an appropriate level of funding.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.